{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bhat K"],"funding":["NIAID NIH HHS","NCI NIH HHS","NIAID"],"pagination":["8-15"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6400303"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["132"],"pubmed_abstract":["OBJECTIVE:Exposure to lethal doses of radiation has severe effects on normal tissues. Exposed individuals experience a plethora of symptoms in different organ systems including the gastrointestinal (GI) tract, summarized as Acute Radiation Syndrome (ARS). There are currently no approved drugs for mitigating GI-ARS. A recent high-throughput screen performed at the UCLA Center for Medical Countermeasures against Radiation identified compounds containing sulfonylpiperazine groups with radiation mitigation properties to the hematopoietic system and the gut. Among these 1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine (Compound #5) efficiently mitigated gastrointestinal ARS. However, the mechanism of action and target cells of this drug is still unknown. In this study we examined if Compound #5 a"],"journal":["Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"],"pubmed_title":["1-(4-nitrobenzenesulfonyl)-4-penylpiperazine increases the number of Peyer's patch-associated regenerating crypts in the small intestines after radiation injury."],"pmcid":["PMC6400303"],"funding_grant_id":["U19 AI067773","P50 CA211015","R01 CA200234","U19 AI067769","AI067769"],"pubmed_authors":["Ramanathan R","Duhachek-Muggy S","Saki M","Damoiseaux R","Pajonk F","Bhat K","McBride WH","Alli C","Whitelegge J","Schaue D","Medina P","Vlashi E"],"additional_accession":[]},"is_claimable":false,"name":"1-(4-nitrobenzenesulfonyl)-4-penylpiperazine increases the number of Peyer's patch-associated regenerating crypts in the small intestines after radiation injury.","description":"OBJECTIVE:Exposure to lethal doses of radiation has severe effects on normal tissues. Exposed individuals experience a plethora of symptoms in different organ systems including the gastrointestinal (GI) tract, summarized as Acute Radiation Syndrome (ARS). There are currently no approved drugs for mitigating GI-ARS. A recent high-throughput screen performed at the UCLA Center for Medical Countermeasures against Radiation identified compounds containing sulfonylpiperazine groups with radiation mitigation properties to the hematopoietic system and the gut. Among these 1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine (Compound #5) efficiently mitigated gastrointestinal ARS. However, the mechanism of action and target cells of this drug is still unknown. In this study we examined if Compound #5 a","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Mar","modification":"2025-04-22T03:03:23.544Z","creation":"2020-05-22T11:33:21Z"},"accession":"S-EPMC6400303","cross_references":{"pubmed":["30825974"],"doi":["10.1016/j.radonc.2018.11.011"]}}